Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

Adma Biologics (ADMA) closed at $17.50 in the latest trading session, marking a +1.16% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.54%. Elsewhere, the Dow gained 1.05%, while the tech-heavy Nasdaq added 0.56%.

The infectious disease drug developer's shares have seen a decrease of 3.24% over the last month, not keeping up with the Medical sector's loss of 1.89% and the S&P 500's gain of 0.74%.

The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.57 per share and a revenue of $0 million, signifying shifts of +16.33% and 0%, respectively, from the last year.

Investors should also note any recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.66% higher. Adma Biologics currently has a Zacks Rank of #3 (Hold).

In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 20.35. This signifies a discount in comparison to the average Forward P/E of 20.39 for its industry.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 94, finds itself in the top 39% echelons of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research